Curve Therapeutics adds to its leadership team

Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development.

The appointments continue the strong momentum at Curve following the recent appointment of Simon Jonesas chief financial (CFO) and chief operating officer (COO).

Curve noted that Dr Hoekema is a highly experienced and successful biotech executive with 40 years’ experience in the industry. He served as chief business officer and member of the executive committee at Galapagos Pharma (Nasdaq: GLPG) for 18 years, with responsibility spanning M&A, business development and IP. During his time at Galapagos, he led multiple pharma partnerships, acquisitions and divestments, including two landmark deals with Gilead. He was also part of the team that completed successful IPOs on Euronext (2005) and Nasdaq (2015). Andre serves as a member of the supervisory advisory boards of Artax Biopharma, Fibrocor Therapeutics and Mimetas BV.